| Title : Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial - Lannfelt_2008_Lancet.Neurol_7_779 |
| Author(s) : Lannfelt L , Blennow K , Zetterberg H , Batsman S , Ames D , Harrison J , Masters CL , Targum S , Bush AI , Murdoch R , Wilson J , Ritchie CW |
| Ref : Lancet Neurol , 7 :779 , 2008 |
| Abstract : Lannfelt_2008_Lancet.Neurol_7_779 |
| ESTHER : Lannfelt_2008_Lancet.Neurol_7_779 |
| PubMedSearch : Lannfelt_2008_Lancet.Neurol_7_779 |
| PubMedID: 18672400 |
Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW (2008)
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial
Lancet Neurol
7 :779
Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, Ritchie CW (2008)
Lancet Neurol
7 :779